Literature DB >> 25878227

Use of multiple immunosuppressive agents in recalcitrant ACANTHAMOEBA scleritis.

Estera Igras1, Conor Murphy1.   

Abstract

A 48-year-old woman who is a contact lens wearer presented with unilateral ACANTHAMOEBA keratitis, confirmed by PCR, which responded initially to topical polyhexamethylene biguanide (PHMB) and brolene. Three months later, despite continued treatment, she developed diffuse anterior scleritis with severe pain and marked scleral injection but without evidence of recurrence keratitis. Oral non-steroidal anti-inflammatories and oral high-dose corticosteroids were added without success. Subsequent treatment with intravenous methylprednisolone and high-dose cyclosporine led to a temporary improvement. Re-presenting with signs of recurrent scleritis and severe pain, the antitumor necrosis factor monoclonal antibody adalimumab, and later oral cyclophosphamide, were added. This led to complete quiescence of the scleritis. Unfortunately, frequent recurrences of ACANTHAMOEBA keratitis and anterior uveitis occurred on immunosuppression requiring continued treatment with PHMB, brolene and topical corticosteroids. This is the first case of severe refractory ACANTHAMOEBA scleritis requiring the concomitant use of four immunosuppressive agents to achieve continued disease control. The challenges in managing this case are discussed. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25878227      PMCID: PMC4401941          DOI: 10.1136/bcr-2014-208536

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

Review 1.  Acanthamoeba keratitis: diagnosis and treatment update 2009.

Authors:  John K G Dart; Valerie P J Saw; Simon Kilvington
Journal:  Am J Ophthalmol       Date:  2009-08-05       Impact factor: 5.258

2.  Comparison of molecular diagnostic methods for the detection of Acanthamoeba spp. from clinical specimens submitted for keratitis.

Authors:  Krishna Khairnar; Gurdip S Tamber; Filip Ralevski; Dylan R Pillai
Journal:  Diagn Microbiol Infect Dis       Date:  2011-06-11       Impact factor: 2.803

3.  Acanthamoeba sclerokeratitis: treatment with systemic immunosuppression.

Authors:  Graham A Lee; Trevor B Gray; John K G Dart; Carlos E Pavesio; Linda A Ficker; D Frank P Larkin; Melville M Matheson
Journal:  Ophthalmology       Date:  2002-06       Impact factor: 12.079

4.  Acanthamoeba sclerokeratitis.

Authors:  P J Dougherty; P S Binder; B J Mondino; B J Glasgow
Journal:  Am J Ophthalmol       Date:  1994-04-15       Impact factor: 5.258

5.  An extraordinary endocytobiont in Acanthamoeba sp. isolated from a patient with keratitis.

Authors:  P Scheid; L Zöller; S Pressmar; G Richard; R Michel
Journal:  Parasitol Res       Date:  2008-01-22       Impact factor: 2.289

6.  Laboratory diagnosis of amoebic keratitis: comparison of four diagnostic methods for different types of clinical specimens.

Authors:  Andrea K Boggild; Donald S Martin; Theresa Yuling Lee; Billy Yu; Donald E Low
Journal:  J Clin Microbiol       Date:  2009-03-25       Impact factor: 5.948

7.  Acanthamoeba sclerokeratitis.

Authors:  Katayoon B Ebrahimi; W Richard Green; Rhonda Grebe; Albert S Jun
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-09       Impact factor: 3.117

Review 8.  Relevance of free-living amoebae as hosts for phylogenetically diverse microorganisms.

Authors:  Patrick Scheid
Journal:  Parasitol Res       Date:  2014-05-15       Impact factor: 2.289

9.  Acanthamoeba sclerokeratitis. Determining diagnostic criteria.

Authors:  M J Mannis; R Tamaru; A M Roth; M Burns; C Thirkill
Journal:  Arch Ophthalmol       Date:  1986-09

10.  Risk factors for acanthamoeba keratitis in contact lens users: a case-control study.

Authors:  C F Radford; A S Bacon; J K Dart; D C Minassian
Journal:  BMJ       Date:  1995-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.